Skip to main navigation
×
CLOSE
Home
Development Programs
VX15 Immuno-Oncology
VX15 Neurology
VX18 Neurology
VX15 Autoimmune
NKT Vaccine
NKT Vaccine
ActivMAb
®
Vaccinia Display
Capabilities
Optimization
Target Identification
Publications
News & Publications
News
Publications
Careers
Corporate
Management
Partners
Contact
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Home
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab
Neurology
Pepinemab
Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
News
Publications
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Careers
Contact Us
ActivMAb
®
Vaccinia
Antibody Discovery
Antigen Virus
Protein Optimization
Antigen Discovery
Antibody Optimization
ActivMAb
®
Contact
Science in the service of medicine
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab Neurology
Pepinemab Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
News
Publications
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Careers
Contact Us
ActivMAb
®
Vaccinia
Antibody Discovery
Antigen Virus
Protein Optimization
Antigen Discovery
Antibody Optimization
Contact Us
Investors
Investor Overview
News Releases
Events
Presentations
Stock Information
Corporate Governance
Financial Information
Investor Services
Shareholder Tools
Print Page
RSS Feeds
E-mail Alerts
IR Contacts
LinkedIn
Twitter
Filter by content type
(-)
News
(151)
Filter by form group
Filter by year
2024
(6)
2023
(20)
2022
(15)
2021
(18)
2020
(17)
2019
(20)
2018
(11)
2017
(3)
2016
(6)
2015
(13)
2014
(7)
2013
(4)
2012
(3)
2011
(5)
2010
(3)
Search
News
Vaccinex Announces Publication of VX15/2503 Non-clinical Toxicology Studies
News
Vaccinex, Inc. announces the initiation of a Phase 2 clinical trial of its investigational VX15/2503 antibody in Huntington’s disease (the SIGNAL trial)
News
Vaccinex announces publication on the generation, characterization and preclinical evaluation of its lead clinical-stage antibody VX15/2503
News
Vaccinex announces publication of results from a Phase I trial of anti-Semaphorin 4D antibody, VX15/2503, in patients with advanced solid tumors
News
Vaccinex to present its ActivMAb® Antibody Discovery Technology at the 2015 PEGS Europe Summit
News
Vaccinex Announces Publication of Vaccinex-Authored Review of SEMA4D in Oncoimmunology
News
Vaccinex provided corporate sponsorship and presented information on its current SIGNAL clinical trial (phase 2 trial of VX15 antibody in Huntington’s disease) at the 2015 Huntington Study Group Annual Meeting in Tampa, Fl
News
Vaccinex Inc. Completes Enrollment of Cohort A in its SIGNAL Clinical Trial, a Randomized Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503 in Subjects at Risk for or with Early Signs of Huntington’s Disease
News
Vaccinex, Inc. to Host Key Opinion Leader Luncheon on Huntington’s Disease
News
Vaccinex and Catalent Biologics to Collaborate on Antibody-Drug Conjugate Development
Pagination
Previous page
‹‹
Page 4
Next page
››